Effects of Melatonin Levels on Neurotoxicity of the Medial Prefrontal Cortex in a Rat Model of Parkinson’s Disease

Yan Li¹, Shu-Mei Wang¹, Lei Guo¹, Jian Zhu², Ying Wang³, Lei Li¹, Yan-Xin Zhao¹

¹Department of Neurology, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong 250013, China
²General Medical Teaching and Research Section, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong 250013, China
³Department of Medical Imaging, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong 250013, China
⁴Department of Medical Imaging, Shandong Provincial Hospital, Jinan, Shandong 250014, China

Abstract

Background: Damage of the medial prefrontal cortex (mPFC) results in similar characteristics to the cognitive deficiency seen with the progress of Parkinson’s disease (PD). Since the course of mPFC damage is still unclear, our study aimed to investigate the effects of melatonin (MT) on neurotoxicity in the mPFC of a rat model of PD.

Methods: One hundred and fifty-four normal, male Wistar rats were randomly divided into the following five groups: normal + normal saline (NS), normal + 6-hydroxydopamine (6-OHDA), sham pinealectomy (PX) + 6-OHDA, PX + 6-OHDA, and MT + 6-OHDA. 6-OHDA was injected into the right substantia nigra pars compacta (SNc) and ventral tegmental area (VTA) of each group, except normal + NS, 60 days after the PX. In the MT treatment group, MT was administered immediately after the intraperitoneal injection at 4 p.m. every day, for 14 days. Neuronal apoptosis in the mPFC was examined using the TUNEL method, while the expression of tyrosine hydroxylase (TH), Bax, and Bcl-2 in this region was measured using immunohistochemistry. The concentration of malondialdehyde (MDA) in the mPFC was examined using the thiobarbituric acid method.

Results: Rats in the normal + 6-OHDA and sham PX + 6-OHDA groups were combined into one group (Group N + 6-OHDA) since there was no significant discrepancy between the groups for all the detected parameters. Apoptosis of cells in the NS, MT + 6-OHDA, N + 6-OHDA, and PX + 6-OHDA groups was successively significantly increased (He = 256.25, P < 0.001). The gray value of TH (+) fibers in the NS, MT + 6-OHDA, N + 6-OHDA, and PX + 6-OHDA groups was also successively significantly increased (F = 99.33, P < 0.001). The staining intensities of Bax and Bcl-2 were as follows: Group NS +/+, Group MT + 6-OHDA ++/+, Group N + 6-OHDA ++/+, and PX + 6-OHDA +++/+. The concentrations of MDA in the NS, MT + 6-OHDA, N + 6-OHDA, and PX + 6-OHDA groups was significantly increased in sequence (He = 296.309, P < 0.001).

Conclusions: Neuronal damage of the VTA by 6-OHDA might induce VTA-mPFC nerve fibers to undergo anterograde nerve damage, in turn inducing transneuronal damage of the mPFC. PX significantly exacerbated the neurotoxicity in the mPFC, which was induced by the neuronal injury of the VTA. However, MT replacement therapy significantly alleviated the neurotoxicity in the mPFC.

Key words: Medial Prefrontal Cortex; Melatonin; Pinealectomy; Tyrosine Hydroxylase; Ventral Tegmental Area

INTRODUCTION

Parkinson’s disease (PD) is a neurodegenerative disease, where the reduction of dopamine (DA) in the substantia nigra pars compacta (SNc)-striatal, ventral tegmental area (VTA)-cortex, and VTA-limbic pathways leads to the motor and nonmotor symptoms (NMS) of the disease.[1, 2, 3, 4] Being a crucial part of the cortex-limbic system-striatal pathway, the medial prefrontal cortex (mPFC) connects with many nuclear groups in the brain. It was mainly innervated by dopaminergic nerve fiber projections from the midbrain VTA.[5] DA is an important neurotransmitter for mPFC function. Damages in the dopaminergic nerve system of the mPFC can result in persistent cognitive and behavioral disorder. Further, cognitive disorder is one of the major manifestations of PD NMS.[11] A recent meta-analysis...
demonstrated that the emergence of NMS (such as memory loss, depression, apathy, and anxiety) often occurs earlier than motor symptoms. The NMS of approximately 50% of patients with PD has not been given enough attention.\[^5\] Although the mechanisms underlying this disease are still unclear, PD is widely believed to be caused by multiple factors. Melatonin (MT) is an indole neural endocrine hormone that is mainly secreted by the pineal gland. It regulates the circadian rhythm. Studies have shown that the incidence of PD increases with ages, while the level of MT in \textit{in vivo} reduces with ages.\[^6\] Further, the level of MT is lower in patients with PD than their normal, aged counterparts.\[^6\] Thus, it has been speculated that the level of MT is potentially related to the occurrence of PD. Currently, only a few studies have focused on the relationship between MT levels \textit{in vivo} and PD. Further, the results of basic studies led to different conclusions.\[^7\] Previous studies have also emphasized movement symptoms of PD, with little focus on the NMS of PD. Up to now, the relationship between MT levels \textit{in vivo} and mPFC pathological variation in rat model of the disease or patients with PD has not been reported.

6-hydroxydopamine (6-OHDA) can selectively damage catecholamine neurons and their fiber tips, resulting in neurotoxicity via multiple routes that lead to symptoms similar to PD.\[^4\] 6-OHDA can damage hemi-midbrain SNc and VTA DA neurons, which allows the rat model of PD to better simulate disease pathogenesis. Tyrosine hydroxylase (TH) is the rate-limiting enzyme of DA biosynthesis, while Bax promotes cell apoptosis and Bcl-2 inhibits it. Malondialdehyde (MDA) is a degradation product of lipid peroxidation, which indirectly reflects the degree of cell damage. It is an important indicator of oxidative stress in the human body. In the current study, we aimed to further understand the effect of MT levels \textit{in vivo} on the neurotoxicity of DA neurons in the mPFC of the 6-OHDA hemi-PD rat model. To do this, cell apoptosis, the expression of TH(+) fibers, Bax, and Bcl-2, and the MDA content were analyzed, following a pinealectomy (PX) and MT replacement therapy.

**METHODS**

**Materials**

A total of 154 normal male Wistar rats, weighing 301–320 g each and aged 12 months, were provided by the animal experiment center of Shandong University. The experimental protocols were approved by the Institutional Animal Care and Use Committee of Shandong University. The rats were placed in a quiet environment and could freely drink water and eat food. The rats were housed under a light/dark environment, with 12 h of light (8:00–20:00) and 12 h of darkness (20:00–8:00).

**Animal model**

The animals were randomly divided into the following five groups: normal + normal saline (NS; \(n = 30\)), normal + 6-OHDA (\(n = 30\)), sham PX + 6-OHDA (\(n = 30\)), PX + 6-OHDA (\(n = 32\)), and MT + 6-OHDA (\(n = 32\)). The same experimental protocol was performed on control rats, except that the pineal gland was not removed. The rats were bred for 60 days after the operation, and then anesthetized with an intraperitoneal injection of 10% chloral hydrate (0.5 mg/100 g). The head of each rat was horizontally fixed onto the mouse stereotactic instrument and the three-dimensional coordinates of the right SNc and VTA were determined in reference to the atlas by Ming and Yun.\[^9\] A total of 10 \(\mu\)g of 6-OHDA was injected at each point, with the equivalent dose of NS injected into rats in the normal + NS group. Rats in the MT treatment group were immediately administered MT (dissolved into 10% ethanol NS, dosage of 0.5 mg/100 g), via an intraperitoneal injection, and then continued to receive an MT injection at 16:00 every afternoon, for 14 days. Behavioral observation was performed at 14 days after the 6-OHDA injection. Apomorphine (0.5 mg/kg) was administered with an intraperitoneal injection, and the number of total rotating circles within 30 min was recorded by taking notes oneself for each rat. An average value \(>7\) r/min indicated that a successful PD model had been established. Rats that failed to meet these standards were excluded from the analysis.

**Main reagents and equipment**

The main reagents used in the current study included the following: \textit{in situ} cell apoptosis kits (Roche, USA), MT (Sigma, USA), TH primary antibody (Santa Cruz Biotechnology, USA), and Bax, Bcl-2, SP, DAB kits, and primary antibody (Beijing Zhongshan Reagents, China). We also used MDA kits that were provided by Boster Biological Technology (Wuhan, China). The following equipment were also used: Synergy-HT multi-function microplate reader (Bio-Tek, USA), ultrasonic homogenizer (Omni, USA), and rat brain stereotactic instrument (NeuroStar, Germany).

**Sample selection and pathological observation**

A total of 16 PD rats in each group were anesthetized and perfused with 4% paraformaldehyde for 2 h, 14 days after 6-OHDA was injected. Thereafter, they were decapitated and the cerebra were removed. Samples from Bregma of 4.6–1.6 mm were selected, fixed for 6 h, dehydrated till transparent, and embedded in wax. The sample was then sliced into 4-mm sections. A total of 20 sections, within 4.6–2.6 mm Bregma, were selected and five sections were then dyed. Cell apoptosis was detected by TUNEL staining. The expressions of TH, Bax, and Bcl-2 were analyzed using immunohistochemistry (IHC). A total of ten residual circles within 30 min was recorded by taking notes oneself for each rat. An average value \(>7\) r/min indicated that a successful PD model had been established. Rats that failed to meet these standards were excluded from the analysis.
measured using thiobarbituric acid within 10 h. It must be noted that the pineal gland was not incompletely removed when each brain was picked up. During feeding, nine rats in Group N + 6-OHDA, six rats in Group PX + 6-OHDA, and six rats in Group MT + 6-OHDA were excluded due to postoperative acroparalysis, difficulty in feeding and death, or failure to effectively model PD.

**Statistical analysis**

Since there were no significant differences between groups such as normal + 6-OHDA and sham PX + 6-OHDA, these two groups were combined into one group named N + 6-OHDA. The mPFC in the hemisphere that was administered with 6-OHDA injection was analyzed. The number of apoptotic cells in 5 mPFC slices was counted, using 10 × 20-fold light microscope. Three fields were selected for each slice, and the numbers were averaged.

The characteristics of cell apoptosis under light microscopy were as follows: nuclear condensation, dyed brown, uneven coloring, and typically ring form. A few apoptotic cells in the NS group were not in a constant position. Compared with the NS group, the number of apoptotic cells was apparently increased in all the PD groups and scattered among the cortex layers, most in layers III–VI. The number of apoptotic cells in the NS, MT + 6-OHDA, N + 6-OHDA, and PX + 6-OHDA groups was significantly increased in sequence ($Hc = 256.25, P < 0.001$) [Table 1 and Figure 1a–1d].

**Tyrosine hydroxylase immunohistochemistry staining**

Sparse and fine TH(+) nerve fibers in the NS group were scattered in the cortical layers, mainly in layer IV. In the PD model groups, TH(+) nerve fibers were more sparse and fine, with only a few TH(+) dots. The TH(+) gray values in the nerve fibers in the NS, MT + 6-OHDA, N + 6-OHDA, and PX + 6-OHDA groups were significantly increased successively ($F = 99.33, P < 0.001$) [Table 1 and Figure 2a–2d].

**Bax and Bcl-2 immunohistochemistry staining**

Bax and Bcl-2 were scattered in the cortical layers, Bax was most in layers III–VI. The results were as follows: Bax: Group NS+, Group MT + 6-OHDA ++, Group N + 6-OHDA +++, Group PX + 6-OHDA +++. Bcl-2: all groups +.

**Determination of malondialdehyde concentration**

Compared with the NS group, the concentration of MDA in the mPFC of the PD group was significantly increased. The concentrations of MDA in the NS, MT + 6-OHDA, N + 6-OHDA, and PX + 6-OHDA groups were significantly increased in sequence ($Hc = 296.309, P < 0.001$) [Table 2].

**Results**

**TUNEL staining**

The characteristics of cell apoptosis under light microscopy were as follows: nuclear condensation, dyed brown, uneven coloring, and typically ring form. A few apoptotic cells in the NS group were not in a constant position. Compared with the NS group, the number of apoptotic cells was apparently increased in all the PD groups and scattered among the cortex layers, most in layers III–VI. The number of apoptotic cells in the NS, MT + 6-OHDA, N + 6-OHDA, and PX + 6-OHDA groups was significantly increased in sequence ($Hc = 256.25, P < 0.001$) [Table 1 and Figure 1a–1d].

**Discussion**

The PFC is a part of the cerebral cortex, which refers to the full frontal cortex, with the exception of the primary motor cortex and secondary motor cortex. The PFC contains areas that differ in structure and function, and is mainly divided into the mPFC and orbitofrontal cortex. The mPFC is additionally divided into the infralimbic cortex, prelimbic cortex, and dorsal anterior cingulate.[10] The mPFC is mainly innervated by dopaminergic nerve fiber projections from the VTA and forms the midbrain cortex dopaminergic system, which controls recognition and thinking ability.[10] Cognitive deficiency can occur at different stages during the course of PD, and its characteristics are similar to mPFC damage.[11] Previous imaging studies demonstrated...
a significant reduction in the volume of the frontal lobe of patients with PD. Pathological changes in the mPFC in PD could be attributed to either the reduction of mPFC DA fiber projections, due to VTA DA damage, or to other factors leading to neurotoxicity in these brain area, which has not yet been reported.

Anatomical studies have demonstrated that mPFC cells are divided into six layers. The VTA-mPFC dopaminergic nerve fibers are mainly projected into layer IV, namely in the granule cell layer. The results of this experiment demonstrated the following: TH(+) nerve fibers in Group NS were scattered throughout the cortical layers, most in layer IV, which corroborate with a previous anatomical study. Compared with the NS group, there was an increase in gray values of TH(+) nerve fibers in Group N + 6-OHDA, which indicated a decrease in TH(+) nerve fibers. This result indicated that VTA damage resulting from the injection of 6-OHDA into the midbrain could cause anterograde nerve damage to the projected nerve fibers. Tompkins et al. adopted the TUNEL approach to determine apoptosis-like changes in mesencephalic dopaminergic neurons in patients with PD. In the current study, compared with the NS group, the number of apoptotic cells in the mPFC of the PD group was increased and scattered throughout the cortical layers, mainly in layers III–IV. This indicated that damage to the VTA could cause postsynaptic neurons with synaptic contact to elicit neurotoxic effects, i.e., orthograde transneuronal damage. This can be defined as the phenomenon by which neurons completely lose the innervation of afferent neuron, consequently leading to nerve cell atrophy and degeneration. Although it is known that cell apoptosis participates in this process of neurotoxicity, the mechanisms that underlie this are still not clear. Further, non-VTA-mPFC dopaminergic postsynaptic neurons in other layers of the mPFC cortex also caused cells to be apoptotic. Therefore, we postulated that post- and pre-synaptic transneuronal damage between each cortical layer could be one of the reasons. This finding corroborated with previous studies by Sweet et al. who demonstrated that damage of the SNc and VTA was associated with a decrease in nerve fibers in a wide range of brain regions. Further, its projection fiber terminal neurons were also significantly reduced.

TH(+) nerve fibers in Group N + 6-OHDA and sham PX + 6-OHDA; PX: Pinealectomy; MT: Melatonin; mPFC: Medial prefrontal cortex; SD: Standard deviation; NS: Normal saline.

**Table 1: Comparison of the number of apoptosis and TH(+) fiber gray values in mPFC in each group (mean ± SD)**

| Group          | Number of animals | TUNEL | Hc   | F   | P    | TH(+) fibers | F   | P    |
|----------------|-------------------|-------|------|-----|------|--------------|-----|------|
| NS             | 16                | 1.33 ± 0.11* | 40.50 | 256.25 | <0.001 | 141.23 ± 15.69* | 99.330 | <0.001 |
| MT + 6-OHDA    | 16                | 11.21 ± 2.98* | 134.23 | 296.25 | <0.001 | 157.56 ± 14.33* | 99.330 | <0.001 |
| N + 6-OHDA     | 16                | 15.88 ± 3.02* | 205.09 | 262.18 | <0.001 | 169.41 ± 16.76* | 181.96 ± 15.42* | <0.001 |
| PX + 6-OHDA    | 16                | 20.36 ± 3.97* | 262.18 | 296.25 | <0.001 | 169.41 ± 16.76* | 181.96 ± 15.42* | <0.001 |

*Comparison between two groups and †comparison between two groups, all P<0.05. TH: Tyrosine hydroxylase; 6-OHDA: 6-hydroxydopamine; N + 6-OHDA: Normal + 6-OHDA and sham PX + 6-OHDA; PX: Pinealectomy; MT: Melatonin; mPFC: Medial prefrontal cortex; SD: Standard deviation; NS: Normal saline.

**Table 2: Comparison of the concentrations of MDA in mPFC in each group, mean ± SD (nmol/mg protein)**

| Group          | Number of animals | The concentrations of MDA | Mean rank | Hc   | F   | P    |
|----------------|-------------------|---------------------------|-----------|------|-----|------|
| NS             | 10                | 110.74 ± 7.45*            | 40.50     | 296.25 | <0.001 | 296.309 | <0.001 |
| MT + 6-OHDA    | 10                | 154.12 ± 5.05*            | 122.28    | 157.56 | 14.33 | <0.001 |
| N + 6-OHDA     | 10                | 169.22 ± 5.24*            | 198.82    | 169.41 | 16.76 | <0.001 |
| PX + 6-OHDA    | 10                | 198.58 ± 8.11*            | 280.40    | 181.96 | 15.42 | <0.001 |

*Comparison between two groups, all P<0.05; MDA: Malondialdehyde; 6-OHDA: 6-hydroxydopamine; N + 6-OHDA: Normal + 6-OHDA and sham PX + 6-OHDA; PX: Pinealectomy; MT: Melatonin; mPFC: Medial prefrontal cortex; NS: Normal saline.

**Figure 2:** Immunohistochemistry for expression of TH(+) fibers in mPFC (SP, original magnification ×100). (a) Group NS. (b) Group MT + 6-OHDA. (c) Group N + 6-OHDA. (d) Group PX + 6-OHDA. mPFC: Medial prefrontal cortex; NS: Normal saline; MT: Melatonin; 6-OHDA: 6-hydroxydopamine; N: Normal + Sham pinealectomy; PX: Pinealectomy; TH: Tyrosine hydroxylase.
was ++/+, which verified that VTA damage caused by 6-OHDA could promote apoptosis in the mPFC, by enhancing Bax expression. The latter finding corroborated with the apparent increase of apoptotic cells in the mPFC of Group N + 6-OHDA, compared with that in the NS group, which verified that the imbalance of Bax/Bcl-2 is a possible reason for the apparent increase in cell apoptosis induced by VTA damage in mPFC. MDA is a degradation product of lipid peroxidation. The level of MDA indirectly reflects the degree of cell damage, with a high concentration of MDA leading to apoptosis. In the current experiment, the content of MDA in the mPFC of the N + 6-OHDA group was significantly higher than that in the NS group, indicating that 6-OHDA-induced VTA damage caused an oxidative stress reaction in the mPFC. The reason for this is not clear. We postulated that the marked increase in MDA is one of the ways in which VTA damage induces increased cell apoptosis in the mPFC.

Previous studies demonstrated that MT shortage in vivo was related to PD, with MT replacement therapy partially improving PD symptoms. Other studies, have yielded contrary results. Some therapeutic trials demonstrated that, although MT was effective in impeding the progression of Alzheimer’s disease, it was not an effect for PD. In the current study, compared with Group N + 6-OHDA, the number of apoptotic cells in the mPFC in Group MT + 6-OHDA was significantly reduced, while the number of TH(+) nerve fibers was significantly increased (i.e., since the TH(+) nerve fiber gray values were significantly reduced). The results demonstrated that MT apparently alleviated the effect, i.e., the apparent increase of apoptosis of mPFC cells and reduction of TH(+) nerve fibers in mPFC, which was induced by VTA damage. This suggested that MT replacement therapy may have a protective effect on PD. The putative mechanisms by which MT reduces neurotoxicity have been outlined below. First, the antioxidant stress response, i.e., the ability of MT to scavenge free radicals, is 2, 4, and 14 times that below. First, the antioxidant stress response, i.e., the ability of MT to scavenge free radicals, is 2, 4, and 14 times that of Vitamin E, glutathione, and mannitol, respectively. MT is selectively occupied by the respiratory chain and not shared by other antioxidants. In the antioxidant system, MT is the only hormone that matches age. Second, MT inhibits the inflammatory response. Third, MT inhibits aggregation of α-Synuclein and other abnormal proteins, consequently reducing their neurotoxicity. Further, MT can increase the mRNA and protein expression of neurotrophic factors (i.e., GDNF), whereas 6-OHDA inhibits the expression of GDNF. Finally, MT can inhibit apoptosis by regulating Bax/Bcl-2 gene expression. In the current study, compared to the N + 6-OHDA group, the apoptosis of cells in the mPFC of the PX + 6-OHDA group was significantly higher. Further, the number of TH(+) fibers was significantly reduced (i.e., since the gray value of TH(+) fibers was significantly increased). This finding indicated that MT lacks an apparently aggravated effect on the increase of apoptosis of mPFC cells and reduction of TH(+) nerve fibers in the mPFC, which were induced by VTA damage, supporting the theory that there is an association between MT deficiency and PD onset. MT is mainly produced in the pineal gland. After PX, the level of MT decreased significantly in rats, which reduced its neuroprotective effect. Compared to other tissues, brain tissue contains a large amount of polyunsaturated fatty acids and has more iron ions that have a catalytic activity. Further, the brain contains very low level of antioxidant enzymes, making it susceptible to neuronal toxic factors. Thus, mPFC neurotoxicity that was induced by a 6-OHDA injection to the VTA was aggravated after PX.

In the current study, the expression of Bax/Bcl-2 in mPFC was as follows: Group N + 6-OHDA was ++/+ and Group PX + 6-OHDA was +++, indicating that PX aggravated the upregulation of Bax/Bcl-2, which was induced by the 6-OHDA injection to the SNc and VTA. This validated the theory that PX worsened the cell apoptosis induced by VTA damage by modulating the expression of Bax/Bcl-2. This experiment indicated that MT reduced the mPFC cell apoptosis induced by VTA damage. However, since the expression of Bax/Bcl-2 was ++/+ in the MT + 6-OHDA group and ++/+ in the N + 6-OHDA, this suggested that MT reduced apoptotic cells in mPFC by a mechanism that was not dependent on Bax or Bcl-2. This finding did not corroborate with previous findings. In the current study, the content of mPFC MDA in the MT + 6-OHDA group was significantly lower than that in the N + 6-OHDA group. Further, the content of MDA, in the PX + 6-OHDA group, was significantly increased, and thus, for the significant increase in the level of lipid peroxides of mPFC by the 6-OHDA injection to the VTA, MT alleviated this effect, while a deficiency in MT had an aggravated effect. The results proved that MT had an anti-lipid peroxidation effect, which is consistent with previous findings.

Although we studied the relationship between MT level and mPFC nerve damage in a 6-OHDA rat model of PD, we only focused on the lipid peroxidation and Bax/Bcl-2 expression in relation to the mechanism of MT action. Thus, we did not analyze other mechanism in depth, which remains to be elucidated in future experimental studies.

We confirmed that a deficiency in MT could aggravate mPFC nerve damage in a 6-OHDA rat model of PD, and that MT replacement therapy could alleviate this damage, providing a certain reference for the early diagnosis and treatment of PD.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

REFERENCES

1. Sgambato-Faure V, Buggia V, Gilbert F, Lévesque D, Benabid AL, Berger F, et al. Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats. J Neuropathol Exp Neurol 2005;64:936-47. doi: 10.1097/01.jnen.0000186922.42592.b7.
2. Hajós, M., Hajós-Korcósk, E., Sharp, T. Role of the medial prefrontal cortex in 5-HT1A receptor-induced inhibition of 5-HT neuronal activity in the rat. Br J Pharmacol 1999;126:1741-50. doi: 10.1038/sj.bjp.0702510.

3. Kraus, M.F., Maki, P.M. Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: Case studies and review. J Neuropsychiatry Clin Neurosci 1997;9:222-30. doi: 10.1176/jnp.9.2.222.

4. Aarsland, D., Bronnick, K., Williams-Gray, C., Weintraub, D., Marder, K., Kulisevsky, J., et al. Mild cognitive impairment in Parkinson disease: A multicenter pooled analysis. Neurology 2010;75:1062-9. doi: 10.1212/WNL.0b013e3181f9d0e.

5. Chaudhuri, K.R., Prieto-Jurcynska, C., Naidu, Y., Mitra, T., Frades-Payo, B., Tluk, S., et al. The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: An international study using the nonmotor symptoms questionnaire. Mov Disord 2010;25:704-9. doi: 10.1002/mds.22668.

6. Srinivasan, V., Spence, D.W., Pandi-Perumal, S.R., Brown, G.M., Cardinali, D.P. Melatonin in mitochondrial dysfunction and related disorders. Int J Alzheimers Dis 2011;2011:326320. doi: 10.4061/2011/326320.

7. Willis, G.L., Turner, E.J. Primary and secondary features of Parkinson's disease improve with strategic exposure to bright light: A case series study. Chronobiol Int 2007;24:521-37. doi: 10.1080/07420520701420717.

8. Hwang, C.K., Chun, H.S. Isoliquiritigenin isolated from licorice Glycyrrhiza uralensis prevents 6-hydroxydopamine-induced apoptosis in dopaminergic neurons. Biosci Biotechnol Biochem 2012;76:536-43. doi: 10.1271/bbb.110842.

9. Ming, B.X., Yun, S.S. The Stereotaxic Atlas of the Rat Brain. 1st ed. Beijing: People's Medical Publishing House; 1991.

10. Spencer, R.C., Devilbiss, D.M., Berridge, C.W. The cognition-enhancing effects of psychostimulants involve direct action in the prefrontal cortex. Biol Psychiatry 2015;77:940-50. doi: 10.1016/j.biopsych.2014.09.013.

11. Doubois, B., Pillon, B. Cognitive deficits in Parkinson's disease. J Neurol 1997;244:2-8.

12. Nishio, Y., Hirayama, K., Takeda, A., Hosokai, Y., Ishioka, T., Suzuki, K., et al. Corticolumbic gray matter loss in Parkinson's disease without dementia. Eur J Neurol 2010;17:1090-7. doi: 10.1111/j.1468-1331.2010.02980.x.

13. Tompkins, M.M., Basgall, E.J., Zamrini, E., Hill, W.D. Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. Am J Pathol 1997;150:119-31.

14. Sweet, J.A., Walter, B.L., Gunalan, K., Chaturvedi, A., McIntyre, C.C., Miller, J.P., et al. Fiber tractography of the axonal pathways linking the basal ganglia and cerebellum in Parkinson disease: Implications for targeting in deep brain stimulation. J Neurosurg 2014;120:988-96. doi: 10.3171/2013.12.JNS131537.

15. Anaya-Martinez, V., Martinez-Marcos, A., Martinez-Fong, D., Aceves, J., Erelj, D. Substantia nigra compacta neurons that innervate the reticular thalamic nucleus in the rat also project to striatum or globus pallidus: Implications for abnormal motor behavior. Neuroscience 2006;143:477-86. doi: 10.1016/j.neuroscience.2006.08.033.

16. Cheng, EH, Kirsch DG, Clem RJ, Ravi R, Kastan MB, Bedi A, et al. Conversion of bcl-2 to a Bax-like death effector by caspases. Science 1997;278:1966-8. doi: 10.1126/science.278.5345.1966.

17. Hartmann, A., Michel PP, Troade JD, Mouatt-Prigent A, Faucheux BA, Ruberg, M., et al. Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson’s disease? J Neurochem 2001;76:1785-93. doi: 10.1046/j.1471-4159.2001.0060x.

18. Litvinenko IV, Krasakov IV, Tikhomirova OV. Sleep disorders in Parkinson’s disease without dementia: A comparative randomized controlled study of melatonin and clonazepam. Zh Nevrol Psikhiatr Im S S Korsakova 2012;112:26-30.

19. Gutiérrez-Valdez AL, Anaya-Martínez V, Ordoñez-Librado JL, García-Ruiz R, Torres-Esquível C, Moreno-Rivera M, et al. Effect of chronic L-dopa or melatonin treatments after dopamine deafferentation in rats: Dyskinesia, motor performance, and cytological analysis. ISRN Neurol 2012;2012:360379. doi: 10.5402/2012/360379.

20. Olakowska E, Marcel W, Kotul ska K, Lewin-Kowalik J. Role of melatonin in neurodegenerative diseases. Neurotox Res 2005;7:293-318. doi: 10.1007/BF03033887.

21. Pieri C, Marra M, Moroni F, Recchioni R, Marcheselli F. Melatonin: A peroxyl radical scavenger more effective than Vitamin E. Life Sci 1994;55:PL271-6.

22. Ozsoy O, Yildirim FB, Ogut E, Kaya Y, Tanriover G, Parlk H, et al. Melatonin is protective against 6-hydroxydopamine-induced oxidative stress in a hemiparkinsonian rat model. Free Radic Res 2015;49:1004-14. doi: 10.1080/10715762.2015.1027198.

23. Pinato L, da Silveira Cruz-Machado S, Franco DG, Campos LM, Cecon E, Fernandes PA, et al. Selective protection of the cerebellum against intracerebroventricular LPS is mediated by local melatonin synthesis. Brain Struct Funct 2015;220:827-40. doi: 10.1007/s00429-013-0686-4.

24. Sac-Ung K, Uéda K, Govitrapong P, Phansuwan-Pujito P. Melatonin reduces the expression of alpha-synuclein in the dopamine containing neuronal regions of amphetamine-treated postnatal rats. J Pineal Res 2012;52:128-37. doi: 10.1111/j.1600-079X.2011.00927.

25. Zhang L, Zhang HQ, Liang XY, Zhang HF, Zhang T, Liu FE, et al. Melatonin ameliorates cognitive impairment induced by sleep deprivation in rats: Role of oxidative stress, BDNF and caMKII. Behav Brain Res 2013;256:72-81. doi: 10.1016/j.bbr.2013.07.051.

26. Yildirim FB, Ozsoy O, Tanriover G, Kaya Y, Ogut E, Gemic B, et al. Melatonin in mitochondrial dysfunction and related disorders. Int J Alzheimers Dis 2011;2011:326320. doi: 10.4061/2011/326320.

27. Hua, ZX, Cai, LJ. Melatonin free-radical effect and its mechanism. Chin Pharmacol 1997;15:24-7.